NCT01950455View on ClinicalTrials.gov

Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes

PHASE3TerminatedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

January 31, 2018

Study Completion Date

January 31, 2018

Conditions
Parkinson's Syndrome
Interventions
DRUG

NAV5001

A single intravenous dose of 8.0 ± 1.0 mCi

Trial Locations (2)

32806

Compass Research, Orlando

85004

Xenoscience, Inc., Phoenix

Sponsors
All Listed Sponsors
lead

Navidea Biopharmaceuticals

INDUSTRY